Jeff Binder was named president, CEO and chairman of the board of directors for Immucor in June 2015.
A healthcare leader for more than two decades, Binder previously served as president and CEO of another TPG company, Biomet, a leading designer, manufacturer and marketer of surgical and non-surgical products used primarily by orthopedic surgeons and other musculoskeletal medical specialists.
Before Biomet, Binder held the role of senior vice president of diagnostic operations with Abbott Laboratories; president of Abbott Spine; and president and CEO of Spinal Concepts. Prior to Spinal Concepts, Binder served as president of DePuy Orthopedics following its integration with Johnson & Johnson. He also held various senior positions with Howmedica Orthopedics and the Boston Consulting Group. Binder received his bachelor’s degree in applied mathematics from Yale University and his master’s degree in public policy from Princeton University.
In addition to his role as CEO, Binder will also serve as Senior Advisor to TPG. In this role, Binder will advise TPG on its ongoing efforts to maximize the value of its investments in the healthcare industry and continue to play a role advocating for policies that will strengthen the healthcare system.
Dominique Petitgenet was named vice president and chief financial officer for Immucor in March 2012 and named vice president, international transfusion diagnostics in May 2014.
He joined Immucor from Merial, a division of Sanofi, where he served as chief financial officer. Merial is a multibillion-dollar worldwide leader in the animal health industry with sales in 150 countries. Petitgenet has held a variety of leadership positions with Merial since 2001. Previously, Petitgenet held positions with Rhodia, Rhone-Poulenc Group and the Montedison Group. He earned his master’s degree in finance from Paris Dauphine University.